This inventor holds 1 USPTO granted patent. Top assignee: Novo Nordisk A/s. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000
Title: Michael Albert Crider: Inventor in Ocular Disease Treatment
Introduction
Michael Albert Crider is an inventor associated with Monroe, Louisiana, and Novo Nordisk A/S. His patent work concerns a potential treatment approach for diseases affecting the eye.
Latest Patents
Crider is associated with 1 patent, titled “Use of Somatostatin Agonists and Antagonists for Treating Diseases.” The invention describes using nonpeptide somatostatin receptor ligands, or their pharmaceutically acceptable salts, that have high or selective affinity for the SSTR4 receptor. It proposes preparing medicines to treat adverse conditions affecting the retina or iris-ciliary body, including high intraocular pressure and deep ocular infections. Potential applications named in the patent include glaucoma, stromal keratitis, iritis, retinitis, cataract, and conjunctivitis.
Career Highlights
Crider’s listed patent work connects pharmaceutical research with potential treatments for ocular conditions. His company affiliation is Novo Nordisk A/S.
Collaborations
Michael Ankersen and Carsten Enggaard Stidsen are identified as Crider’s coworkers.
Conclusion
Michael Albert Crider’s patent focuses on SSTR4-targeting compounds as a proposed approach to treating several eye diseases and related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile